Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis

References

• Fuchs D, Bograd A, Pfister IB, Bächtiger J, Spindler J, Hoogewoud F, et al. Efficacy of TNF-Alpha inhibitors to control inflammation and prevent secondary complications in non-infectious uveitis: a real-life experience from Switzerland. Ocul Immunol Inflammation. 2023;2023:1–6. doi:10.1080/09273948.2023.2263095.
   Google Scholar
• Leclercq M, Desbois AC, Domont F, Maalouf G, Touhami S, Cacoub P, et al. Biotherapies in Uveitis. J Clin Med. 2020;9(11):3599. doi:10.3390/jcm9113599.
   PubMed Web of Science ®Google Scholar
• Sharma S, Kharel R, Parajuli S, Jha S. Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal. Ann Med Surg (Lond). 2023;85(5):1486–1489. doi:10.1097/MS9.0000000000000546.
   PubMed Web of Science ®Google Scholar
• Touhami S, Gueudry J, Leclercq M, Touitou V, Ghembaza A, Errera MH, et al. Perspectives for immunotherapy in noninfectious immune mediated uveitis. Expert Rev Clin Immunol. 2021;17(9):977–989. doi:10.1080/1744666X.2021.1956313.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, Hughes DA, McKay A, Rosala-Hallas A, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technol Assess. 2019;23(15):1–140. doi:10.3310/hta23150.
   PubMed Web of Science ®Google Scholar
• Goto H, Zako M, Namba K, Hashida N, Kaburaki T, Miyazaki M, et al. Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflammation. 2019;27(1):40–50. doi:10.1080/09273948.2018.1491605.
   PubMed Web of Science ®Google Scholar
• Horton S, Jones AP, Guly CM, Hardwick B, Beresford MW, Lee RW, et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE trial. Am J Ophthalmol. 2019;207:170–174. doi:10.1016/j.ajo.2019.06.007.
   PubMed Web of Science ®Google Scholar
• Li B, Li H, Zhang L, Zheng Y. Efficacy and safety of adalimumab in noninfectious uveitis: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:673984. doi:10.3389/fphar.2021.673984.
   PubMed Web of Science ®Google Scholar
• Mase O, Qasem M, Beare N. Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis. BMJ Open Ophthalmol. 2023;8(1):e001303. doi:10.1136/bmjophth-2023-001303.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, et al. Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2021;128(6):899–909. doi:10.1016/j.ophtha.2020.10.036.
   PubMed Web of Science ®Google Scholar
• Gamalero L, Simonini G, Ferrara G, Polizzi S, Giani T, Cimaz R. Evidence-based treatment for uveitis. Isr Med Assoc J. 2019;21:475–479.
   PubMed Web of Science ®Google Scholar
• Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019;30(3):138–150. doi:10.1097/ICU.0000000000000562.
   PubMed Web of Science ®Google Scholar
• El-Shabrawi Y, Rath T, Heiligenhaus A. Janus kinase inhibitors: next-generation treatment for uveitis. Klinische Monatsblatter fur Augenheilkunde. 2022;239(5):695–701. doi:10.1055/a-1741-8104.
   PubMedGoogle Scholar
• Renton WD, Jung J, Palestine AG. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Rev. 2022;10(10):Cd013818. doi:10.1002/14651858.CD013818.pub2.
   PubMedGoogle Scholar
• Maccora I, Land P, Miraldi Utz V, Angeles-Han ST. Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis. Expert Rev Clin Immunol. 2023;19(7):689–692. doi:10.1080/1744666X.2023.2207823.
   PubMed Web of Science ®Google Scholar
• Wen J, Hu H, Chen M, Yang H, Zhao Y, Liu Y. Role of Janus Kinase (JAK) inhibitor in autoimmune ocular inflammation: a systematic review. J Immunol Res. 2021;2021:2324400. doi:10.1155/2021/2324400.
   PubMed Web of Science ®Google Scholar
• Melki I, Frémond ML. JAK inhibition in juvenile idiopathic arthritis (JIA): better understanding of a promising therapy for refractory cases. J Clin Med. 2023;12(14):4695. doi:10.3390/jcm12144695.
   PubMed Web of Science ®Google Scholar
• Bing SJ, Lyu C, Xu B, Wandu WS, Hinshaw SJ, Furumoto Y, et al. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Mol Vis. 2020;26:641–651.
   PubMed Web of Science ®Google Scholar
• Ueki Y, Takimoto-Ito R, Saito MK, Tanizaki H, Kambe N. Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome. Front Immunol. 2023;14:1211240. doi:10.3389/fimmu.2023.1211240.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cai Z, Mo X, Zeng H. Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients. Pediatr Rheumatol. 2021;19(1):160. doi:10.1186/s12969-021-00634-x.
   PubMed Web of Science ®Google Scholar
• Álvarez-Reguera C, Prieto-Peña D, Herrero-Morant A, Sánchez-Bilbao L, Martín-Varillas JL, González-López E, et al. Clinical and immunological study of tofacitinib and baricitinib in refractory Blau syndrome: case report and literature review. Ther Adv Musculoskelet Dis. 2022;14:1759720x221093211. doi:10.1177/1759720X221093211.
   Web of Science ®Google Scholar
• Baquet-Walscheid K, Heinz C, Rath T, Scheel M, Heiligenhaus A. Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: a case report. Ocul Immunol Inflammation. 2023;31(5):1079–1080. doi:10.1080/09273948.2022.2069128.
   PubMed Web of Science ®Google Scholar
• Schneider J, Schalenbourg A, Dudler J, Guex-Crosier Y. Intermediate uveitis in an HLA-B27-Positive patient treated with upadacitinib. Klinische Monatsblatter fur Augenheilkunde. 2022;239(4):572–574. doi:10.1055/a-1766-6739.
   PubMedGoogle Scholar
• Huang Z, Jiang Q, Chen J, Liu X, Gu C, Tao T, et al. Therapeutic effects of upadacitinib on experimental autoimmune uveitis: insights from single-cell analysis. Invest Ophthalmol Vis Sci. 2023;64(12):28. doi:10.1167/iovs.64.12.28.
   PubMed Web of Science ®Google Scholar
• Su Y, Tao T, Liu X, Su W. JAK-STAT signaling pathway in non-infectious uveitis. Biochem Pharmacol. 2022;204:115236. doi:10.1016/j.bcp.2022.115236.
   PubMed Web of Science ®Google Scholar
• Pleyer U, Algharably EA, Feist E, Kreutz R. Small molecules as therapy for uveitis: a selected perspective of new and developing agents. Expert Opin Pharmacother. 2017;18(13):1311–1323. doi:10.1080/14656566.2017.1361408.
   PubMed Web of Science ®Google Scholar
• Davydova A, Kurochkina Y, Goncharova V, Vorobyeva M, Korolev M. The interleukine-17 cytokine family: role in development and progression of spondyloarthritis, current and potential therapeutic inhibitors. Biomedicines. 2023;11(5):1328. doi:10.3390/biomedicines11051328.
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i43–i54. doi:10.1093/rheumatology/key276.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Thorne JE, Bansie R, Braun J, van Hagen PM, Bodaghi B. Biologic therapy for HLA-B27-associated ocular disorders. Ocul Immunol Inflammation. 2017;25(2):169–178. doi:10.1080/09273948.2016.1234625.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Klotsche J, Simonini G, Edelsten C, Angeles-Han ST, Bangsgaard R, et al. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC). Pediatr Rheumatol Online J. 2019;17(1):66.
   PubMed Web of Science ®Google Scholar
• Cecchin V, Zannin ME, Ferrari D, Pontikaki I, Miserocchi E, Paroli MP, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2018;45(8):1167–1172. doi:10.3899/jrheum.171006.
   PubMed Web of Science ®Google Scholar
• Zhou J, Huang W, Zhang Z, Luo L, Ren F, Huang D, et al. Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment. Clin Rheumatol. 2023;42(12):3251–3255. doi:10.1007/s10067-023-06724-3.
   PubMed Web of Science ®Google Scholar
• Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child. 2019;104(3):246–250. doi:10.1136/archdischild-2018-315060.
   PubMed Web of Science ®Google Scholar
• Leal I, Steeples LR, Wong SW, Giuffrè C, Pockar S, Sharma V, et al. Update on the systemic management of noninfectious uveitis in children and adolescents. Surv Ophthalmol. 2023. doi:10.1016/j.survophthal.2023.01.002.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Murakami T, Nishitsuka K, Takakubo Y, Takagi M, Yamashita H. Effectiveness of baricitinib in refractory seronegative rheumatoid arthritis and uveitis: a case report. Front Med. 2021;8:764067. doi:10.3389/fmed.2021.764067.
   Web of Science ®Google Scholar
• Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847–851. doi:10.1007/s10067-019-04875-w.
   PubMed Web of Science ®Google Scholar
• Cohen S, Reddy V. Janus kinase inhibitors: efficacy and safety. Curr Opin Rheumatol. 2023;35(6):429–434. doi:10.1097/BOR.0000000000000972.
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024;20(2):101–115. doi:10.1038/s41584-023-01062-9.
   PubMed Web of Science ®Google Scholar
• Lanzillotta M, Boffini N, Barone E, Cincinelli G, Gerardi MC, Luciano N, et al. Safety of Janus kinase inhibitors: a real-world multicenter retrospective cohort study. J Rheumatol. 2023;50(12):1581–1586. doi:10.3899/jrheum.2023-0145.
   Google Scholar
• Jeong S, George MD, Mikuls TR, England BR, Sauer B, Cannon GW, et al. Changes in patterns of use of advanced therapies following emerging data about adverse events in patients with rheumatoid arthritis from the veterans affairs health system. ACR Open Rheumatology. 2023;5(10):563–567. doi:10.1002/acr2.11602.
   PubMedGoogle Scholar
• Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis. 2023;82(1):119–129. doi:10.1136/ard-2022-222259.
   PubMed Web of Science ®Google Scholar
• Mattay SS, Zamani M, Saturno D, Loftus EV Jr., Ciorba MA, Yarur A, et al. Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis. Clin Gastroenterol Hepatol. 2023. doi:10.1016/j.cgh.2023.09.033.
   PubMedGoogle Scholar
• Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, et al. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the select phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023;82(9):1130–1141. doi:10.1136/ard-2023-223916.
   PubMed Web of Science ®Google Scholar
• Campanaro F, Zaffaroni A, Cacioppo E, Cappelli A, Bertù L, Donadini MP, et al. Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis. Rheumatology (Oxford). 2023;62(10):3245–3255. doi:10.1093/rheumatology/kead211.
   PubMed Web of Science ®Google Scholar
• Song YJ, Cho SK, Kim JY, You SH, Kim H, Jung SY, et al. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: a nationwide population-based study. Semin Arthritis Rheumatism. 2023;61:152214. doi:10.1016/j.semarthrit.2023.152214.
   PubMed Web of Science ®Google Scholar
• Ahn SS, Han M, Jung I, Kim HW. Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs. Clin Exp Rheumatol. 2023;41(9):1908–1916. doi:10.55563/clinexprheumatol/ins2z2.
   PubMed Web of Science ®Google Scholar
• Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82(8):1059–1067. doi:10.1136/ard-2023-224049.
   PubMed Web of Science ®Google Scholar
• Liu T, Gao R, Li L, Wu B, Wu F. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the food and drug administration adverse event reporting system. Int J Clin Pharm. 2023;45(6):1483–1491. doi:10.1007/s11096-023-01634-5.
   PubMed Web of Science ®Google Scholar
• Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729–749. doi:10.1007/s13555-023-00892-5.
   PubMed Web of Science ®Google Scholar
• Toriola SL, Satnarine T, Zohara Z, Adelekun A, Seffah KD, Salib K, et al. Recent clinical studies on the effects of tumor necrosis factor-alpha (TNF-α) and Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) antibody therapies in refractory cutaneous sarcoidosis: a systematic review. Cureus. 2023;15(9):e44901. doi:10.7759/cureus.44901.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL surveillance trial. Ann Rheum Dis. 2023;82(3):331–343. doi:10.1136/ard-2022-222543.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao B. Janus kinase inhibitor—Tofacitinib associated with pemphigus: an analysis of the FDA adverse event reporting system data. Expert Opin Drug Saf. 2023;22(12):1317–1320. doi:10.1080/14740338.2023.2248872.
   PubMed Web of Science ®Google Scholar
• Huang F, Luo ZC. Adverse drug events associated with 5mg versus 10mg tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2019;38(2):523–534. doi:10.1007/s10067-018-4299-4.
   PubMed Web of Science ®Google Scholar
• Uchida T, Iwamoto N, Fukui S, Morimoto S, Aramaki T, Shomura F, et al. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study. Rheumatology (Oxford). 2023;62(10):3358–3365. doi:10.1093/rheumatology/kead079.
   PubMed Web of Science ®Google Scholar
• Manoharan A, Atmakur H, Dutta Majumder P, Biswas J. Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib. J Ophthal Inflamm Infect. 2023;13(1):45. doi:10.1186/s12348-023-00359-w.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kircik L, Simpson E, Brinker D, Katoh N, Rueda MJ, et al. Pooled analysis of baricitinib tolerability in patients with atopic dermatitis in relation to acne, headache, and gastrointestinal events from 8 clinical trials. Dermatitis®. 2023;34(4):308–314. doi:10.1089/derm.2022.0027.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):335–343. doi:10.1136/annrheumdis-2021-221276.
   PubMed Web of Science ®Google Scholar
• Wu CY, Wang Q, Shi J, Zhang XY, Du R, Gu JR, et al. Safety and effectiveness of baricitinib in Chinese patients with moderate-to-severe rheumatoid arthritis: 24-week results from a post-marketing safety study. Rheumatol Ther. 2023;10(6):1609–1622. doi:10.1007/s40744-023-00596-4.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Nash P, Yamaoka K, Mysler E, Khan N, Camp HS, et al. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Ann Rheum Dis. 2022;81(2):206–213. doi:10.1136/annrheumdis-2021-220822.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Mysler E, Tanaka Y, Da Silva-Tillmann B, Shaw T, Liu J, et al. Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program. Drug Saf. 2021;44(5):515–530. doi:10.1007/s40264-020-01036-w.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Li Y, et al. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. Arthritis Res Ther. 2023;25(1):172. doi:10.1186/s13075-023-03128-1.
   PubMed Web of Science ®Google Scholar
• Gelato F, Mastorino L, Quaglino P, Cavaliere G, Ortoncelli M, Ribero S. Ocular adverse events in patients with atopic dermatitis treated with upadacitinib: a real-life experience. Dermatitis®. 2023;34(5):445–447. doi:10.1089/derm.2022.0063.
   PubMedGoogle Scholar
• Nguyen HO, Tiberio L, Facchinetti F, Ripari G, Violi V, Villetti G, et al. Modulation of human dendritic cell functions by phosphodiesterase-4 inhibitors: potential relevance for the treatment of respiratory diseases. Pharmaceutics. 2023;15(9):2254. doi:10.3390/pharmaceutics15092254.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li Z, Li H, Su W, Xie Y, Pan Y, et al. Apremilast regulates the teff/treg balance to ameliorate uveitis via PI3K/AKT/FoxO1 signaling pathway. Front Immunol. 2020;11:581673. doi:10.3389/fimmu.2020.581673.
   PubMed Web of Science ®Google Scholar
• Le Joncour A, Régnier P, Maciejewski-Duval A, Charles E, Barete S, Fouret P, et al. Reduction of neutrophil activation by phosphodiesterase 4 blockade in Behçet’s disease. Arthritis & Rheumatology (Hoboken, NJ). 2023;75(9):1628–1637. doi:10.1002/art.42486.
   PubMed Web of Science ®Google Scholar
• Wakiya R, Ushio Y, Ueeda K, Kameda T, Shimada H, Nakashima S, et al. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet’s disease. Dermatol Ther. 2022;35(8):e15616. doi:10.1111/dth.15616.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. 2022;8(1):e002012. doi:10.1136/rmdopen-2021-002012.
   PubMed Web of Science ®Google Scholar
• Witte T. [Janus kinase inhibitors]. Z Rheumatol. 2022;81(2):94–99. doi:10.1007/s00393-021-01125-w.
   PubMed Web of Science ®Google Scholar
• Zhang B, Dömling A. Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021). Expert Opin Ther Pat. 2022;32(11):1161–1173. doi:10.1080/13543776.2022.2143264.
   PubMed Web of Science ®Google Scholar
• Huang JX, Wei JC. Janus kinase inhibitors: a future all-rounder in axial spondyloarthritis? Immunotherapy. 2023;15(15):1195–1198. doi:10.2217/imt-2023-0176.
   PubMedGoogle Scholar
• Bitossi A, Mattioli I, Bettiol A, Palermo A, Malandrino D, Bacherini D, et al. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review. Expert Rev Clin Immunol. 2023;19(5):549–560. doi:10.1080/1744666X.2023.2193687.
   PubMed Web of Science ®Google Scholar
• Caporali R, Germinario S, Kacsándi D, Choy E, Szekanecz Z. Start RA treatment - biologics or JAK-inhibitors? Autoimmun Rev. 2023:103429. doi:10.1016/j.autrev.2023.103429.
   PubMedGoogle Scholar
• Acharya NR, Ebert CD, Kelly NK, Porco TC, Ramanan AV, Arnold BF. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in juvenile idiopathic arthritis-associated uveitis stopping trial): study protocol for a randomised controlled trial. Trials. 2020;21(1):887. doi:10.1186/s13063-020-04796-z.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Guly CM, Keller SY, Schlichting DE, de Bono S, Liao R, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021;22(1):689. doi:10.1186/s13063-021-05651-5.
   PubMed Web of Science ®Google Scholar
• Welzel T, Winskill C, Zhang N, Woerner A, Pfister M. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials. Pediatr Rheumatol. 2021;19(1):46. doi:10.1186/s12969-021-00514-4.
   PubMed Web of Science ®Google Scholar
• Tolentino MJ, Tolentino AJ. Investigational drugs in clinical trials for macular degeneration. Expert Opin Investig Drugs. 2022;31(10):1067–1085. doi:10.1080/13543784.2022.2113375.
   PubMed Web of Science ®Google Scholar